PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO
May 1, 2011, 00:00
10.1016/j.jval.2011.02.459
https://www.valueinhealthjournal.com/article/S1098-3015(11)00598-5/fulltext
Title :
PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00598-5&doi=10.1016/j.jval.2011.02.459
First page :
A82
Section Title :
Selected Health Care Treatment Studies
Open access? :
No
Section Order :
1023